ZVRA - Zevra Therapeutics, Inc.
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will present at the H.
BOSTON, May 12, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will present at the H.C. Wainwright BioConnect Investor Conference in New York, NY on Tuesday, May 19, 2026, at 9:00 a.m. ET.
Zevra Therapeutics, Inc. (ZVRA) Q1 2026 Earnings Call Transcript
Zevra Therapeutics (ZVRA) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to a loss of $0.06 per share a year ago.
Q1 2026 net revenue of $36.2 million , a 78% increase over Q1 2025 Completed $50.0 million sale of SDX portfolio to Commave Therapeutics Operational execution fueled strong cash position of $236.8 million Company to host conference call and webcast TODAY, May 6, 2026 , at 4:30 p.m. ET BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today reported its financial results for the first quarter ended March 31, 2026.
Zevra Therapeutics (NASDAQ: ZVRA - Get Free Report) and Cassava Sciences (NASDAQ: FLNA - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, valuation, dividends, profitability, earnings, analyst recommendations and risk. Insider and Institutional Ownership 35.0% of Zevra
Zevra Therapeutics, Inc. (NASDAQ: ZVRA - Get Free Report) has received an average recommendation of "Moderate Buy" from the nine analysts that are currently covering the firm, MarketBeat Ratings reports. Two research analysts have rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 12 month price
BOSTON, March 20, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that the Company has granted as of March 18, 2026 an equity inducement award to Justin Renz, the Company's new Chief Financial Officer pursuant to the Company's 2023 Employment Inducement Award Plan (as amended and/or restated, the “Inducement Award Plan”). The equity award was approved by the Compensation Committee of the Board of Directors in accordance with Nasdaq Rule 5635(c)(4) and made as a material inducement to Mr. Renz upon acceptance of employment with Zevra.
BOSTON, March 16, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced an agreement under which Commave Therapeutics SA (Commave) will purchase Zevra's serdexmethylphenidate (SDX) portfolio, including AZSTARYS® and KP1077, for $50 million. "We are pleased to have reached a mutually beneficial agreement with Commave regarding the sale of our entire SDX portfolio," said Neil F.
It also posted 44% net revenue growth for the period. Both headline figures crushed the consensus analyst estimates.
Zevra Therapeutics delivered robust FY25 results, with 350% revenue growth to $106.5M and a GAAP EPS of $1.40, driven by Miplyffa's commercial launch. Miplyffa's rapid adoption in the ultra-rare NPC market, supported by expanded payer coverage and diagnostic initiatives, underpins ZVRA's strong commercial momentum. ZVRA trades at discounted valuation multiples (16.9x forward P/E, 10.7x EV/EBIT), reflecting market caution over one-time income and earnings sustainability.
ZVRA up in pre-market trading on better-than-expected Q4 results. Gainers include BRTX, COOT, BIYA, SOAR, MTEN, MDCX, NXGL, ABTC, and VALN. Losers include GSIW, POM, ARQ, RAIL, and NTZ.
Zevra Therapeutics, Inc. (ZVRA) Q4 2025 Earnings Call Transcript
CELEBRATION, Fla., March 02, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced it will report corporate and financial results for the fourth quarter and full year 2025 on Monday, March 9, 2026, via a news release after the market close, and will host a conference call/audio webcast at 4:30 p.m. ET that day.
CELEBRATION, Fla., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Zevra Therapeutics, Inc. (NasdaqGS: ZVRA) (Zevra, or the Company), a commercial-stage company focused on providing therapies for people living with rare disease, today announced that members of Zevra's executive leadership team will present at the Citizens Life Sciences Conference in Miami Beach, FL on Wednesday, March 11, 2026, at 9:00 a.m. ET.
SUNRISE, Fla., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Transpire Bio Inc., an integrated clinical-stage biopharmaceutical company focused on developing inhaled therapeutics for pulmonary and systemic diseases, today announced the appointment of R. LaDuane Clifton as Chief Financial Officer (CFO).
San Diego, California--(Newsfile Corp. - February 19, 2026) - Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation focuses on Zevra's executive officers and whether investor losses may be recovered under federal securities laws.
Zevra Therapeutics, Inc. (NASDAQ: ZVRA - Get Free Report) was the recipient of a large increase in short interest during the month of January. As of January 30th, there was short interest totaling 4,797,728 shares, an increase of 20.2% from the January 15th total of 3,991,736 shares. Currently, 8.7% of the shares of the company are
SAN DIEGO--(BUSINESS WIRE)---- $ZVRA #Zevra--Johnson Fistel, PLLP is investigating potential claims on behalf of investors of Zevra Therapeutics, Inc. (NASDAQ: ZVRA). The investigation focuses on Zevra's executive officers and whether investor losses may be recovered under federal securities laws. What if I purchased Zevra securities? If you purchased Zevra securities and suffered losses on your investment, join our investigation now: Click here to join the investigation. Or for more information, contact Jim Ba.
Real-world and clinical trial data underscore long-term safety and effectiveness in pediatric and adult NPC patients Real-world and clinical trial data underscore long-term safety and effectiveness in pediatric and adult NPC patients